🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the fight against increasingly resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

Cases of gonorrhoea are escalating worldwide, with figures suggesting over 82 million new cases per year. Especially elevated rates are seen in the African continent and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the face of rising global incidence, the spread of superbugs and the very limited available drugs at this time.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Drugs Receive Approval

One new antibiotic, alternatively called a brand name, was cleared by the American regulatory agency in December for use against gonorrhoea. This STI can lead to significant complications, including infertility. Researchers believe that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GSK, was also approved in the same week. This drug, which is employed against UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone marks a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Results and Global Access

According to results published in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which uses a dual-drug approach. The study involved nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians on the front lines have shared hope. The availability of a single-dose, oral treatment such as this is seen as a "critical tool" for managing the epidemic. This is deemed vital to reduce the burden of the illness for people and to halt the transmission of untreatable gonorrhoea worldwide.